Perspectives in Malignant Hematology

A Virtual Forum Designed to Address Clinical Challenges with the Goal to Improve Patient Outcomes

September 22, 2021 – September 25, 2021

This meeting will provide clinical trial safety and efficacy data for approved and emerging agents and combinations being studied for the treatment of hematologic malignancies. Frontline and relapsed/refractory disease are eligible to be discussed. Within each section, there will be a heavy focus on contextualizing the data and application to clinical practice. The impact of COVID-19 on the care of patients with hematologic malignancies can be included throughout, per faculty discretion.

LETTER FROM THE CHAIR

Dear Colleagues:

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.

  • Session I: Stet clita kasd gub consetetur 
  • Session II: At vero eos et accusam 
  • Session III: Sed diam nonumy eirmod tempor 
  • Session V: No sea takimata sanctus est
  • Session IV: Labore et dolore magna aliquyam erat, sed diam voluptua

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et.

Sincerely,

Robert Harrington signature

Faculty Name, MD
Conference Chair

Credentials

Robert Harrington signature

Faculty Name, MD
Conference Chair

Credentials

Robert Harrington signature

Faculty Name, MD
Conference Chair

Credentials

Robert Harrington signature

Faculty Name, MD
Conference Chair

Credentials

CHAIR

 

 

 

 

 

 

 

ENHANCE YOUR EXPERIENCE WITH MEDCHALLENGE!

This event features MedChallenge, a new feature from Medscape that allows you to go head-to-head against your peers in a series of medical questions. Earn points, deepen your knowledge, and fight for the top spot on the leaderboard!

Play Now

 
 

 

Medscape Oncology will make a donation to The Leukemia & Lymphoma Society (LLS): LLS is at the forefront of research, advocacy and patient support in the blood cancer community. As a bonus, Medscape will contribute an additional $10 when you participate in the conference. The Leukemia & Lymphoma Society is not involved in the development of content for this conference.


 

company name

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet. 
 

company name

Lorem ipsum dolor sit amet, consetetur sadipscing elitr, sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat, sed diam voluptua. At vero eos et accusam et justo duo dolores et ea rebum. Stet clita kasd gubergren, no sea takimata sanctus est Lorem ipsum dolor sit amet.